The transaction has a total value of 4.3 billion U.S. dollars and is to be completed in the second quarter of 2019, as Roche announced on Monday.Spark Therapeutics is primarily focused on gene therapies for genetic diseases such as blindness, hemophilia and neurodegenerative diseases.
Spark Therapeutics had been given 2017 as the first company to receive US FDA approval for its gene therapy Luxturna for the treatment of patients with a certain eye disease. The European Commission followed in 2018.
< p > treatment costs 850’000 of dollars
made headlines for the drug at all because of the high cost of treatment: One injection in both eyes costs in the United States 850’000 dollars. However, Spark distributes the drug against the eye disease only in the United States. Outside the US the marketing rights with Roche’s rival Novartis.
The boards of Directors of both companies have already approved the transaction, it said. The offer of 114,50 US dollars per Spark share, represents a premium of 122 per cent compared to the closing price last Friday. Compared to the previous record high for the Spark-share from the beginning of July 2018, the premium is 19 percent.
Hope for a breakthrough in blood disease
The high price is associated mainly with the hope that the results of the research of Sparks in the area of blood disease As the main clinical product candidates of Spark Therapeutics, Roche SPK-8011, a novel gene therapy for the treatment of hemophilia A. This is expected to occur in 2019 in a Phase III study. Roche with its Central Hemlibra strong in the treatment of hemophilia active. (koh/SDA)